WO2000025134A1 - Assays for ligands for nuclear receptors - Google Patents
Assays for ligands for nuclear receptors Download PDFInfo
- Publication number
- WO2000025134A1 WO2000025134A1 PCT/US1999/024956 US9924956W WO0025134A1 WO 2000025134 A1 WO2000025134 A1 WO 2000025134A1 US 9924956 W US9924956 W US 9924956W WO 0025134 A1 WO0025134 A1 WO 0025134A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nuclear receptor
- component
- marking
- binding domain
- interaction
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU12290/00A AU1229000A (en) | 1998-10-23 | 1999-10-22 | Assays for ligands for nuclear receptors |
JP2000578657A JP2002528721A (en) | 1998-10-23 | 1999-10-22 | Assays for nuclear receptor ligands |
EP99971090A EP1137940A4 (en) | 1998-10-23 | 1999-10-22 | Assays for ligands for nuclear receptors |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10539098P | 1998-10-23 | 1998-10-23 | |
US60/105,390 | 1998-10-23 | ||
US13509798P | 1998-12-23 | 1998-12-23 | |
US60/135,097 | 1998-12-23 | ||
US13483699P | 1999-05-19 | 1999-05-19 | |
US60/134,836 | 1999-05-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000025134A1 true WO2000025134A1 (en) | 2000-05-04 |
Family
ID=27379915
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/024956 WO2000025134A1 (en) | 1998-10-23 | 1999-10-22 | Assays for ligands for nuclear receptors |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1137940A4 (en) |
JP (1) | JP2002528721A (en) |
AU (1) | AU1229000A (en) |
WO (1) | WO2000025134A1 (en) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002077229A2 (en) * | 2001-03-01 | 2002-10-03 | Lion Bioscience Ag | Cofactors of the liver x receptor alpha and methods of use |
US6639078B1 (en) | 1998-12-23 | 2003-10-28 | Smithkline Beecham Corporation | Assays for ligands for nuclear receptors |
US6987121B2 (en) | 2002-04-25 | 2006-01-17 | Smithkline Beecham Corporation | Compositions and methods for hepatoprotection and treatment of cholestasis |
US7115640B2 (en) | 2001-12-21 | 2006-10-03 | X-Ceptor Therapeutics, Inc. | Heterocyclic modulators of nuclear receptors |
US7138390B2 (en) | 2001-03-12 | 2006-11-21 | Intercept Pharmaceuticals | Steroids as agonists for FXR |
WO2010004052A2 (en) * | 2008-07-11 | 2010-01-14 | Medizinische Universität Innsbruck | Agonists of nr2f6 for immunosuppression |
US7994352B2 (en) | 2005-05-19 | 2011-08-09 | Intercept Pharmaceuticals, Inc. | Process for preparing 3a(β)-7a(β)-dihydroxy-6a(β)-alkyl-5β-cholanic acid |
US7998986B2 (en) | 2001-12-21 | 2011-08-16 | Exelixis Patent Company Llc | Modulators of LXR |
US8013001B2 (en) | 2001-12-21 | 2011-09-06 | Exelixis, Inc. | Modulators of LXR |
US8114862B2 (en) | 2008-11-19 | 2012-02-14 | Intercept Pharmaceuticals, Inc. | TGR5 modulators and methods of use thereof |
US8410083B2 (en) | 2007-01-19 | 2013-04-02 | Intercept Pharmaceuticals, Inc. | 23-substituted bile acids as TGR5 modulators and methods of use thereof |
US8568997B2 (en) | 2006-11-10 | 2013-10-29 | Dimerix Bioscience Pty Ltd. | Detection system and uses therefor |
WO2014028749A2 (en) | 2012-08-15 | 2014-02-20 | Boston Medical Center Corporation | Production of red blood cells and platelets from stem cells |
US8796249B2 (en) | 2008-07-30 | 2014-08-05 | Intercept Pharmaceuticals, Inc. | TGR5 modulators and methods of use thereof |
US9238673B2 (en) | 2012-06-19 | 2016-01-19 | Intercept Pharmaceuticals, Inc. | Preparation and uses of obeticholic acid |
US9314450B2 (en) | 2011-01-11 | 2016-04-19 | Dimerix Bioscience Pty Ltd. | Combination therapy |
US9498484B2 (en) | 2004-03-12 | 2016-11-22 | Intercept Pharmaceuticals, Inc. | Treatment of fibrosis using FXR ligands |
US9982008B2 (en) | 2012-06-19 | 2018-05-29 | Intercept Pharmaceuticals, Inc. | Preparation and uses of obeticholic acid |
US10987362B2 (en) | 2004-03-12 | 2021-04-27 | Intercept Pharmaceuticals, Inc. | Treatment of fibrosis using FXR ligands |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4803976B2 (en) * | 2003-07-09 | 2011-10-26 | 独立行政法人科学技術振興機構 | Molecular sensor for intracellular IP3 measurement |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4568649A (en) * | 1983-02-22 | 1986-02-04 | Immunex Corporation | Immediate ligand detection assay |
US5670360A (en) * | 1992-03-25 | 1997-09-23 | Novo Nordisk A/S | Mammalian receptors for glucagon-like-peptide-1 (GLP-1), corresponding DNA and recombinant expression systems, and screening assays for GLP-1 agonists and enhancers |
US5776699A (en) * | 1995-09-01 | 1998-07-07 | Allergan, Inc. | Method of identifying negative hormone and/or antagonist activities |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6005086A (en) * | 1995-01-13 | 1999-12-21 | The Salk Institute For Biological Studies | Farnesoid activated receptor polypeptides, and nucleic acid encoding the same |
CN1248916A (en) * | 1997-01-24 | 2000-03-29 | 加利福尼亚大学董事会 | Use of FXR, PPAR 'alpha' and LXR 'alpha' activators to restore barrier function, promote epidermal differentiation and inhibit proliferation |
CA2305711A1 (en) * | 1997-10-07 | 1999-04-15 | Merck & Co., Inc. | Assays for nuclear receptor ligands using fret |
US6410245B1 (en) * | 1998-04-01 | 2002-06-25 | Affymax, Inc. | Compositions and methods for detecting ligand-dependent nuclear receptor and coactivator interactions |
-
1999
- 1999-10-22 EP EP99971090A patent/EP1137940A4/en not_active Withdrawn
- 1999-10-22 JP JP2000578657A patent/JP2002528721A/en active Pending
- 1999-10-22 AU AU12290/00A patent/AU1229000A/en not_active Abandoned
- 1999-10-22 WO PCT/US1999/024956 patent/WO2000025134A1/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4568649A (en) * | 1983-02-22 | 1986-02-04 | Immunex Corporation | Immediate ligand detection assay |
US5670360A (en) * | 1992-03-25 | 1997-09-23 | Novo Nordisk A/S | Mammalian receptors for glucagon-like-peptide-1 (GLP-1), corresponding DNA and recombinant expression systems, and screening assays for GLP-1 agonists and enhancers |
US5776699A (en) * | 1995-09-01 | 1998-07-07 | Allergan, Inc. | Method of identifying negative hormone and/or antagonist activities |
Non-Patent Citations (3)
Title |
---|
MANGELSDORF D.J.: "The RXR Heterodimers and Orphan Receptors", CELL, vol. 83, 15 December 1995 (1995-12-15), pages 841 - 850, XP002922898 * |
MUKHERJEE R.: "Sensitization of Diabetic and Obese Mice to Insulin by Retinoid X Receptor Agaonists", NATURE, vol. 386, 27 March 1997 (1997-03-27), pages 407 - 410, XP002922899 * |
See also references of EP1137940A4 * |
Cited By (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6639078B1 (en) | 1998-12-23 | 2003-10-28 | Smithkline Beecham Corporation | Assays for ligands for nuclear receptors |
US6984650B2 (en) | 1998-12-23 | 2006-01-10 | Smithkline Beecham Corporation | Use of FXR ligands |
WO2002077229A3 (en) * | 2001-03-01 | 2003-12-04 | Lion Bioscience Ag | Cofactors of the liver x receptor alpha and methods of use |
WO2002077229A2 (en) * | 2001-03-01 | 2002-10-03 | Lion Bioscience Ag | Cofactors of the liver x receptor alpha and methods of use |
US8058267B2 (en) | 2001-03-12 | 2011-11-15 | Intercept Pharmaceuticals, Inc. | Steroids as agonists for FXR |
US9732117B2 (en) | 2001-03-12 | 2017-08-15 | Intercept Pharmaceuticals, Inc. | Steroids as agonists for FXR |
US8969330B2 (en) | 2001-03-12 | 2015-03-03 | Intercept Pharmaceuticals, Inc. | Steroids as agonists for FXR |
US7138390B2 (en) | 2001-03-12 | 2006-11-21 | Intercept Pharmaceuticals | Steroids as agonists for FXR |
US10421772B2 (en) | 2001-03-12 | 2019-09-24 | Intercept Pharmaceuticals, Inc. | Steroids as agonists for FXR |
US7786102B2 (en) | 2001-03-12 | 2010-08-31 | Intercept Pharmaceuticals, Inc. | Steroids as agonists for FXR |
USRE48286E1 (en) | 2001-03-12 | 2020-10-27 | Intercept Pharmaceuticals, Inc. | Steroids as agonists for FXR |
US8377916B2 (en) | 2001-03-12 | 2013-02-19 | Intercept Pharmaceuticals, Inc. | Steroids as agonists for FXR |
US8013001B2 (en) | 2001-12-21 | 2011-09-06 | Exelixis, Inc. | Modulators of LXR |
US7998986B2 (en) | 2001-12-21 | 2011-08-16 | Exelixis Patent Company Llc | Modulators of LXR |
US7115640B2 (en) | 2001-12-21 | 2006-10-03 | X-Ceptor Therapeutics, Inc. | Heterocyclic modulators of nuclear receptors |
US6987121B2 (en) | 2002-04-25 | 2006-01-17 | Smithkline Beecham Corporation | Compositions and methods for hepatoprotection and treatment of cholestasis |
US9498484B2 (en) | 2004-03-12 | 2016-11-22 | Intercept Pharmaceuticals, Inc. | Treatment of fibrosis using FXR ligands |
US10987362B2 (en) | 2004-03-12 | 2021-04-27 | Intercept Pharmaceuticals, Inc. | Treatment of fibrosis using FXR ligands |
US10258633B2 (en) | 2004-03-12 | 2019-04-16 | Intercept Pharmaceuticals, Inc. | Treatment of fibrosis using FXR ligands |
US7994352B2 (en) | 2005-05-19 | 2011-08-09 | Intercept Pharmaceuticals, Inc. | Process for preparing 3a(β)-7a(β)-dihydroxy-6a(β)-alkyl-5β-cholanic acid |
US8568997B2 (en) | 2006-11-10 | 2013-10-29 | Dimerix Bioscience Pty Ltd. | Detection system and uses therefor |
US8410083B2 (en) | 2007-01-19 | 2013-04-02 | Intercept Pharmaceuticals, Inc. | 23-substituted bile acids as TGR5 modulators and methods of use thereof |
US9243027B2 (en) | 2007-01-19 | 2016-01-26 | Intercept Pharmaceuticals, Inc. | TGR5 modulators and methods of use thereof |
WO2010004052A3 (en) * | 2008-07-11 | 2010-04-15 | Medizinische Universität Innsbruck | Agonists of nr2f6 for immunosuppression |
WO2010004052A2 (en) * | 2008-07-11 | 2010-01-14 | Medizinische Universität Innsbruck | Agonists of nr2f6 for immunosuppression |
US8796249B2 (en) | 2008-07-30 | 2014-08-05 | Intercept Pharmaceuticals, Inc. | TGR5 modulators and methods of use thereof |
US9540414B2 (en) | 2008-07-30 | 2017-01-10 | Intercept Pharmaceuticals, Inc. | TGR5 modulators and methods of use thereof |
US9650409B2 (en) | 2008-11-19 | 2017-05-16 | Intercept Pharmaceuticals, Inc. | TGR5 modulators and methods of use thereof |
US8114862B2 (en) | 2008-11-19 | 2012-02-14 | Intercept Pharmaceuticals, Inc. | TGR5 modulators and methods of use thereof |
US8445472B2 (en) | 2008-11-19 | 2013-05-21 | Intercept Pharmaceuticals, Inc. | TGR5 modulators and methods of use thereof |
US10525038B2 (en) | 2011-01-11 | 2020-01-07 | Dimerix Bioscience Pty Ltd. | Combination therapy |
US9314450B2 (en) | 2011-01-11 | 2016-04-19 | Dimerix Bioscience Pty Ltd. | Combination therapy |
US11382896B2 (en) | 2011-01-11 | 2022-07-12 | Dimerix Bioscience Pty Ltd. | Method for treating inflammatory disorders |
US10058555B2 (en) | 2011-01-11 | 2018-08-28 | Dimerix Bioscience Pty Ltd. | Combination therapy |
US9982008B2 (en) | 2012-06-19 | 2018-05-29 | Intercept Pharmaceuticals, Inc. | Preparation and uses of obeticholic acid |
US9238673B2 (en) | 2012-06-19 | 2016-01-19 | Intercept Pharmaceuticals, Inc. | Preparation and uses of obeticholic acid |
US10174073B2 (en) | 2012-06-19 | 2019-01-08 | Intercept Pharmaceuticals, Inc. | Preparation and uses of obeticholic acid |
US10155787B2 (en) | 2012-06-19 | 2018-12-18 | Intercept Pharmaceuticals, Inc. | Preparation and uses of obeticholic acid |
US10047117B2 (en) | 2012-06-19 | 2018-08-14 | Intercept Pharmaceuticals, Inc. | Preparation and uses of obeticholic acid |
US9732116B2 (en) | 2012-06-19 | 2017-08-15 | Intercept Pharmaceuticals, Inc. | Preparation and uses of obeticholic acid |
WO2014028749A2 (en) | 2012-08-15 | 2014-02-20 | Boston Medical Center Corporation | Production of red blood cells and platelets from stem cells |
EP3789483A1 (en) | 2012-08-15 | 2021-03-10 | Boston Medical Center Corporation | Production of red blood cells and platelets from stem cells |
Also Published As
Publication number | Publication date |
---|---|
JP2002528721A (en) | 2002-09-03 |
AU1229000A (en) | 2000-05-15 |
EP1137940A4 (en) | 2004-06-02 |
EP1137940A1 (en) | 2001-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1137940A1 (en) | Assays for ligands for nuclear receptors | |
EP1140079B1 (en) | Assays for ligands for nuclear receptors | |
Tamrazi et al. | Estrogen receptor dimerization: ligand binding regulates dimer affinity and DimerDissociation rate | |
Thomsen et al. | Functional assays for screening GPCR targets | |
Chang et al. | Evaluation of ligand-dependent changes in AR structure using peptide probes | |
Tamrazi et al. | Molecular sensors of estrogen receptor conformations and dynamics | |
Liu et al. | A homogeneous in vitro functional assay for estrogen receptors: coactivator recruitment | |
Legros et al. | Characterization of the various functional pathways elicited by synthetic agonists or antagonists at the melatonin MT1 and MT2 receptors | |
Ozers et al. | The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a time-resolved fluorescence resonance energy transfer assay | |
Weatherman et al. | Ligand-selective interactions of ER detected in living cells by fluorescence resonance energy transfer | |
Stanley et al. | Subtype specific effects of peroxisome proliferator-activated receptor ligands on corepressor affinity | |
EP1021462A1 (en) | Assays for nuclear receptor ligands using fret | |
Berger et al. | A PPARγ mutant serves as a dominant negative inhibitor of PPAR signaling and is localized in the nucleus | |
Kanayama et al. | Basis of a high-throughput method for nuclear receptor ligands | |
US6689574B1 (en) | Assays for nuclear receptor agonists and antagonists using fluorescence resonance energy transfer | |
Allikalt et al. | Implementation of fluorescence anisotropy-based assay for the characterization of ligand binding to dopamine D1 receptors | |
Zhou et al. | Use of homogeneous time-resolved fluorescence energy transfer in the measurement of nuclear receptor activation | |
Fujino et al. | In vitro farnesoid X receptor ligand sensor assay using surface plasmon resonance and based on ligand-induced coactivator association | |
Gowda et al. | Development of a coactivator displacement assay for the orphan receptor estrogen-related receptor-γ using time-resolved fluorescence resonance energy transfer | |
Cecon et al. | Functional Investigation of Melatonin Receptor Activation by Homogenous cAMP Assay | |
Berbaum et al. | Comparison of full-length versus ligand binding domain constructs in cell-free and cell-based peroxisome proliferator-activated receptor alpha assays | |
Murata et al. | Piezo Electric Sensor for Endocrine-Disrupting Chemicals Using Receptor–co-factor Interaction | |
EP1876446B1 (en) | Method for detection of substance bound to nuclear receptor | |
Awais et al. | A fluorescent indicator to visualize ligand-induced receptor/coactivator interactions for screening of peroxisome proliferator-activated receptor γ ligands in living cells | |
Lee et al. | Interactions of RXR with coactivators are differentially mediated by helix 11 of the receptor's ligand binding domain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref country code: AU Ref document number: 2000 12290 Kind code of ref document: A Format of ref document f/p: F |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09807908 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999971090 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 578657 Kind code of ref document: A Format of ref document f/p: F |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1999971090 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999971090 Country of ref document: EP |